MLYS

Mineralys Therapeutics Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↓ 0/10
  • Momentum↑ 8/10
Mineralys Therapeutics sales and earnings growth
MLYS Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 10.33%
  • FCF Y/Y↓ -33.31%
Mineralys Therapeutics gross and profit margin trends
MLYS Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -83.20%
Mineralys Therapeutics net debt vs free cash flow
MLYS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Mineralys Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗